Research & Development
Our scientists and cross-functional project teams turn molecules detectable in blood into clinical diagnostic biomarkers and precision medicine tools that inform physicians in the screening, prognosis, diagnosis and monitoring of disease. The potential to address major unmet medical needs and to advance clinical practise through biomarkers continues to be substantial – a significant percentage of healthcare decisions relies on laboratory medicine while only a few hundred tests have been integrated into clinical routine, out of more than 10,000 peptides and proteins thought to circulate in human plasma.
Identification and clinical validation of novel biomarkers
Laboratory medicine and medical in-vitro-diagnostic (IVD) tests offer many opportunities to innovate: To better support physicians in their choice of therapy to improve patient outcomes, to aid clinical laboratories to provide test results faster, easier and more cost effectively, or to help reduce health care spending in general.
Our R&D focus lies in the identification and clinical validation of novel biomarkers, in the automation of biomarker tests through immunoassay technology as well as in the new product development and life cycle management of B·R·A·H·M·S IVD products. We strive, through our strong network of IVD industry partners and on own IVD platforms, to make novel immunoassay tests with proven and meaningful clinical utility available to physicians and laboratories, ultimately to help improving patient care.
We are very much interested to collaborate in bringing science and technology to the laboratory medicine field. Please do not hesitate to contact us with your ideas to advance novel biomarkers and clinical tests, together with you.
Our people
Our people
We are an R&D team of around 80 scientists, engineers, technicians and project managers at two Thermo Fisher Scientific locations, in Hennigsdorf (close to Berlin, Germany) and in Nimes (between Marseilles and Montpellier, France), with a diverse set of activities:
- Biomarker research, including mass spectrometry- and Immunoassay-based proteomics and biobanking
- Immunoassay prototyping, including antibody development
- Immunoassay product development
- Mechanical, electrical and software engineering and instrument product development
- Scientific and technical support to assist in global regulatory submissions and to continuously improve our products
- Intellectual property management
- Portfolio- and project management
Hennigsdorf, Germany
Thermo Fisher Scientific in Hennigsdorf, Germany (close to Berlin)
Nimes, France
Thermo Fisher Scientific in Nimes, France (between Marseilles and Montpellier)
Our products
Our products
With our colleagues and with many external collaborators we design, develop and commercialize regulated, globally available, state-of-the-art IVD solutions for the clinical laboratory as well as for Point-of-Care. These include instrument platforms, software and specialty immunoassays. In addition, we assist other IVD companies in automating B·R·A·H·M·S Biomarkers on their platforms.
B·R·A·H·M·S KRYPTOR GOLD: A new level of performance from a benchtop immunoassay analyzer
Learn more on B·R·A·H·M·S KRYPTOR GOLD >
B·R·A·H·M·S PCT (Procalcitonin) helps to simplify the quest for determining whether an infection is bacterial.
Learn more on B·R·A·H·M·S PCT (Procalcitonin) >
The B·R·A·H·M·S Biomarkers commercial products in an overview
Our partners
Our partners
We connect and collaborate to innovate, with our many R&D colleagues across Thermo Fisher Scientifics’ Life Sciences and Specialty Diagnostics groups, as well as externally: Partnerships with international clinical institutions and consortia, with IVD, pharmaceutical and biotech firms, with academia and inventors are key to success. If you are interested to collaborate with us in bringing novel biomarkers or technology to the clinical diagnostic market, please do not hesitate to reach out to us. We love to learn about your ideas and new concepts, to advance laboratory medicine in the areas of sepsis and critical infections, prenatal screening, cardiovascular and other acute conditions as well as endocrinology and oncology.